research use only
Cat.No.S6291
| Related Targets | PRMT EZH2 MAT2A DNA Methyltransferase LSD1 JMJD G9a/GLP MLL NSD SETD |
|---|---|
| Other FTO Inhibitors | FB23-2 Dac51 Rheic Acid Bisantrene (CS1) |
|
In vitro |
DMSO
: 38 mg/mL
(100.73 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 377.22 | Formula | C18H14Cl2N2O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2243736-35-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=C(C(=NO1)C)C2=CC(=C(NC3=CC=CC=C3C(O)=O)C(=C2)Cl)Cl | ||
| Targets/IC50/Ki |
FTO demethylase
(Cell-free assay) 60 nM
|
|---|---|
| In vitro |
FB23 treatment inhibits acute myeloid leukemia (AML) cells proliferation with IC50 values of 44.8 μM, 23.6 μM for NB4 and MONOMAC6 AML cells. This compound treatment causes the significant suppression of MYC targets, E2F targets, and G2M checkpoint signal cascades, which may contribute to the inhibitory effects of FTO inhibitors and FTO KD on cell cycle and proliferation. This chemical treatments activates apoptosis and p53 pathways. |
| In vivo |
Pharmacological inhibition of FTO by FB23-2 substantially suppresses leukemia progression and prolongs survival. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.